Hudson Valley Investment Advisors Inc. ADV lowered its position in Merck & Company, Inc. (NYSE:MRK) by 0.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,647 shares of the company’s stock after selling 244 shares during the period. Merck & makes up approximately 1.2% of Hudson Valley Investment Advisors Inc. ADV’s holdings, making the stock its 26th largest position. Hudson Valley Investment Advisors Inc. ADV’s holdings in Merck & were worth $4,271,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of MRK. Norges Bank purchased a new position in shares of Merck & during the fourth quarter valued at $1,628,824,000. Dodge & Cox bought a new stake in shares of Merck & during the fourth quarter valued at about $821,068,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Merck & during the fourth quarter valued at about $252,822,000. Bank of Montreal Can increased its stake in shares of Merck & by 49.7% in the first quarter. Bank of Montreal Can now owns 8,991,093 shares of the company’s stock valued at $571,295,000 after buying an additional 2,983,319 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of Merck & by 70.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after buying an additional 2,300,200 shares in the last quarter. 73.46% of the stock is currently owned by institutional investors and hedge funds.
Merck & Company, Inc. (NYSE MRK) traded down 0.57% during midday trading on Friday, hitting $61.49. 8,421,689 shares of the company traded hands. The firm has a market capitalization of $167.71 billion, a PE ratio of 33.29 and a beta of 0.80. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80. The stock’s 50-day moving average is $62.91 and its 200-day moving average is $63.83.
Merck & (NYSE:MRK) last released its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.93 earnings per share. Analysts anticipate that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is currently 76.11%.
TRADEMARK VIOLATION NOTICE: “Merck & Company, Inc. (NYSE:MRK) Position Cut by Hudson Valley Investment Advisors Inc. ADV” was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/hudson-valley-investment-advisors-inc-adv-sells-244-shares-of-merck-company-inc-nysemrk-updated-updated-updated.html.
Several analysts recently issued reports on MRK shares. Zacks Investment Research upgraded Merck & from a “hold” rating to a “buy” rating and set a $72.00 price target for the company in a report on Wednesday, May 10th. J P Morgan Chase & Co increased their price target on Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. BidaskClub downgraded Merck & from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BMO Capital Markets raised their target price on Merck & from $68.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Finally, Vetr upgraded Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 target price for the company in a research note on Monday, May 15th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. Merck & presently has an average rating of “Hold” and an average target price of $69.58.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.